Firms ally to develop drug for cancer, autoimmune disease

05/17/2013 | Genetic Engineering & Biotechnology News

RuiYi and Genor Biopharma agreed to co-develop the former's experimental monoclonal antibody drug RYI-008 against cancer and autoimmune diseases, particularly rheumatoid arthritis, in China. The deal follows RuiYi's announcement that it would use CMC Biologics' CHEF1 high-productivity expression plasmid to speed work on a cell line for RYI-008.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC